IL265194A - Combination of an anti-cd20 antibody, pi3 kinase-delta inhibitor, and anti-pd-1 or anti-pd-l1 antibody for treating hematological cancers - Google Patents
Combination of an anti-cd20 antibody, pi3 kinase-delta inhibitor, and anti-pd-1 or anti-pd-l1 antibody for treating hematological cancersInfo
- Publication number
- IL265194A IL265194A IL265194A IL26519419A IL265194A IL 265194 A IL265194 A IL 265194A IL 265194 A IL265194 A IL 265194A IL 26519419 A IL26519419 A IL 26519419A IL 265194 A IL265194 A IL 265194A
- Authority
- IL
- Israel
- Prior art keywords
- antibody
- kinase
- combination
- hematological cancers
- delta inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662385723P | 2016-09-09 | 2016-09-09 | |
PCT/US2017/050825 WO2018049263A1 (en) | 2016-09-09 | 2017-09-08 | Combination of an anti-cd20 antibody, pi3 kinase-delta inhibitor, and anti-pd-1 or anti-pd-l1 antibody for treating hematological cancers |
Publications (1)
Publication Number | Publication Date |
---|---|
IL265194A true IL265194A (en) | 2019-05-30 |
Family
ID=59969229
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL265194A IL265194A (en) | 2016-09-09 | 2019-03-06 | Combination of an anti-cd20 antibody, pi3 kinase-delta inhibitor, and anti-pd-1 or anti-pd-l1 antibody for treating hematological cancers |
Country Status (13)
Country | Link |
---|---|
US (1) | US20190247399A1 (en) |
EP (1) | EP3509634A1 (en) |
JP (1) | JP2019526595A (en) |
KR (1) | KR20190068521A (en) |
CN (1) | CN110191720A (en) |
AU (1) | AU2017322501A1 (en) |
BR (1) | BR112019004185A2 (en) |
CA (1) | CA3035976A1 (en) |
CL (1) | CL2019000585A1 (en) |
EA (1) | EA201990374A1 (en) |
IL (1) | IL265194A (en) |
MX (1) | MX2019002728A (en) |
WO (1) | WO2018049263A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3027204A1 (en) | 2016-06-29 | 2018-01-04 | Checkpoint Therapeutics, Inc. | Pd-l1-specific antibodies and methods of using the same |
MX2020013936A (en) | 2017-03-20 | 2022-12-01 | Forma Therapeutics Inc | Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators. |
CN108743947B (en) * | 2018-07-04 | 2020-12-15 | 复旦大学附属肿瘤医院 | Pharmaceutical composition for treating B cell lymphoma |
US12053458B2 (en) | 2018-09-19 | 2024-08-06 | Novo Nordisk Health Care Ag | Treating sickle cell disease with a pyruvate kinase R activating compound |
US11001588B2 (en) | 2018-09-19 | 2021-05-11 | Forma Therapeutics, Inc. | Activating pyruvate kinase R and mutants thereof |
WO2020191022A1 (en) * | 2019-03-18 | 2020-09-24 | Forma Therapeutics, Inc. | Inhibiting ubiquitin specific peptidase 9x |
BR112022000684A2 (en) * | 2019-07-15 | 2022-03-03 | Johnson Matthey Plc | Umbralisib monotosylate, process for preparing an amorphous form, amorphous form of umbralisib monotosylate, pharmaceutical composition, and, method of treating disease |
IL314661A (en) * | 2022-02-28 | 2024-09-01 | Jasper Therapeutics Inc | Compositions and methods for depletion of diseased hematopoietic stem cells |
CN115141092A (en) * | 2022-07-27 | 2022-10-04 | 诚达药业股份有限公司 | Synthetic method of anti-lymphoma drug related compound |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
US6190370B1 (en) | 1997-07-25 | 2001-02-20 | Arrow International, Inc. | Devices, systems and methods for determining proper placement of epidural catheters |
FR2807767B1 (en) | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | MONOCLONAL ANTIBODIES ANTI-D |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
FR2844455B1 (en) | 2002-09-13 | 2007-12-14 | Lab Francais Du Fractionnement | TREATMENT OF PATHOLOGIES EXCLUDING IMMUNE RESPONSE BY OPTIMIZED ANTIBODIES |
ES2633311T3 (en) | 2002-12-16 | 2017-09-20 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
JP4511943B2 (en) | 2002-12-23 | 2010-07-28 | ワイス エルエルシー | Antibody against PD-1 and use thereof |
FR2858235B1 (en) | 2003-07-31 | 2006-02-17 | Lab Francais Du Fractionnement | USE OF ANTIBODIES OPTIMIZED IN ADCC TO TREAT LOW PATIENT PATIENTS |
FR2879204B1 (en) | 2004-12-15 | 2007-02-16 | Lab Francais Du Fractionnement | CYTOTOXIC ANTIBODY AGAINST HEMATOPOIETIC B-TYPE HEMATOPOIETIC PROLIFERATIONS |
KR101339628B1 (en) | 2005-05-09 | 2013-12-09 | 메다렉스, 인코포레이티드 | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
DK1907424T3 (en) | 2005-07-01 | 2015-11-09 | Squibb & Sons Llc | HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED death ligand 1 (PD-L1) |
BRPI0812913B8 (en) | 2007-06-18 | 2021-05-25 | Merck Sharp & Dohme | monoclonal antibodies or antibody fragment to human programmed death receptor pd-1, polynucleotide, method of producing said antibodies or antibody fragments, composition comprising them and use thereof |
JP2011500086A (en) * | 2007-10-22 | 2011-01-06 | シェーリング コーポレイション | Fully human anti-VEGF antibodies and methods of use |
RU2531758C2 (en) | 2008-02-11 | 2014-10-27 | Куретек Лтд. | Monoclonal antibodies for tumour treatment |
US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
EA023148B1 (en) | 2008-08-25 | 2016-04-29 | Эмплиммьюн, Инк. | Compositions of pd-1 antagonists and use thereof |
CA2735006A1 (en) | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Pd-1 antagonists and methods of use thereof |
CN114835812A (en) | 2008-12-09 | 2022-08-02 | 霍夫曼-拉罗奇有限公司 | anti-PD-L1 antibodies and their use for enhancing T cell function |
CA3022722A1 (en) | 2009-11-05 | 2011-05-12 | Rhizen Pharmaceuticals S.A. | Pi3k protein kinase modulators |
HUE049647T2 (en) | 2009-11-24 | 2020-09-28 | Medimmune Ltd | Targeted binding agents against b7-h1 |
JP2013512251A (en) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Simultaneous inhibition of PD-L1 / PD-L2 |
BR112013032552A2 (en) | 2011-07-24 | 2017-12-12 | Curetech Ltd | humanized immunomodulatory monoclonal antibody variants |
SG11201402603WA (en) | 2011-11-28 | 2014-06-27 | Merck Patent Gmbh | Anti-pd-l1 antibodies and uses thereof |
BR112014028826B1 (en) | 2012-05-15 | 2024-04-30 | Bristol-Myers Squibb Company | USE OF NIVOLUMAB OR PEMBROLIZUMAB |
EP2870157B1 (en) | 2012-07-04 | 2017-08-30 | Rhizen Pharmaceuticals S.A. | Selective pi3k delta inhibitors |
CA3139031A1 (en) | 2012-10-04 | 2014-04-10 | Dana-Farber Cancer Institute, Inc. | Human monoclonal anti-pd-l1 antibodies and methods of use |
DK3150256T3 (en) * | 2012-11-02 | 2020-08-24 | Tg Therapeutics Inc | COMBINATION OF ANTI-CD20 ANTIBODY AND PI3 CHINESE SELECTIVE INHIBITOR |
CN106661030B (en) | 2014-05-27 | 2020-06-30 | 理森制药股份公司 | Improved forms of PI3K delta selective inhibitors for use in pharmaceutical formulations |
SI3179992T1 (en) * | 2014-08-11 | 2022-09-30 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor, a pd-1 inhibitor and/or a pd-l1 inhibitor |
AU2015314756A1 (en) * | 2014-09-13 | 2017-03-16 | Novartis Ag | Combination therapies of alk inhibitors |
-
2017
- 2017-09-08 MX MX2019002728A patent/MX2019002728A/en unknown
- 2017-09-08 WO PCT/US2017/050825 patent/WO2018049263A1/en unknown
- 2017-09-08 KR KR1020197008508A patent/KR20190068521A/en not_active Application Discontinuation
- 2017-09-08 US US16/331,407 patent/US20190247399A1/en not_active Abandoned
- 2017-09-08 AU AU2017322501A patent/AU2017322501A1/en not_active Abandoned
- 2017-09-08 CN CN201780066399.5A patent/CN110191720A/en active Pending
- 2017-09-08 EA EA201990374A patent/EA201990374A1/en unknown
- 2017-09-08 CA CA3035976A patent/CA3035976A1/en not_active Abandoned
- 2017-09-08 BR BR112019004185A patent/BR112019004185A2/en not_active IP Right Cessation
- 2017-09-08 JP JP2019512763A patent/JP2019526595A/en active Pending
- 2017-09-08 EP EP17772801.1A patent/EP3509634A1/en not_active Withdrawn
-
2019
- 2019-03-06 IL IL265194A patent/IL265194A/en unknown
- 2019-03-07 CL CL2019000585A patent/CL2019000585A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CL2019000585A1 (en) | 2020-05-29 |
US20190247399A1 (en) | 2019-08-15 |
CN110191720A (en) | 2019-08-30 |
KR20190068521A (en) | 2019-06-18 |
AU2017322501A1 (en) | 2019-03-28 |
MX2019002728A (en) | 2019-08-16 |
CA3035976A1 (en) | 2018-03-15 |
WO2018049263A1 (en) | 2018-03-15 |
BR112019004185A2 (en) | 2019-09-03 |
EA201990374A1 (en) | 2019-09-30 |
JP2019526595A (en) | 2019-09-19 |
EP3509634A1 (en) | 2019-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL265194A (en) | Combination of an anti-cd20 antibody, pi3 kinase-delta inhibitor, and anti-pd-1 or anti-pd-l1 antibody for treating hematological cancers | |
HUE065528T2 (en) | Combination of zanubrutinib with an anti-cd20 or an anti-pd-1 antibody for use in treating cancer | |
ZA201902265B (en) | Anti-pd-1 antibodies and their uses | |
IL269336A (en) | Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody | |
IL267804A (en) | Methods of treating cancer with anti-pd-1 antibodies | |
ZA201902533B (en) | Anti-pd-l1 antibodies and variants | |
HK1259426A1 (en) | Anti-pd-l1 antibodies and uses thereof | |
IL273411A (en) | Anti-pd-l1 antibody and uses thereof | |
HK1255604A1 (en) | Anti-pd-l1 antibodies and uses thereof | |
IL248540A0 (en) | Combination of an anti-ccr4 antibody and a 4-1bb agonist for treating cancer | |
DK3458478T3 (en) | ANTI-PD-1 AND ANTI-LAG3 ANTIBODIES FOR CANCER TREATMENT | |
SG11201811762RA (en) | Systems and methods for path determination | |
ZA201807888B (en) | Compositions comprising coformulation of anti-pd-l1 and anti-ctla-4 antibodies | |
HK1250142A1 (en) | Combination of hdac inhibitor and anti-pd-1 antibody for treatment of cancer | |
HK1255916A1 (en) | Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of cancer | |
EP3524268A4 (en) | Use of combination of anti-pd-1 antibody and vegfr inhibitor in preparation of drug for treating cancers | |
HUE053982T2 (en) | Il-2rbeta-selective agonists in combination with an anti-ctla-4 antibody or an an anti-pd-1 antibody | |
IL269718A (en) | Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer | |
EP3548064A4 (en) | Anti-hrs antibodies and combination therapies for treating cancers | |
IL259416A (en) | Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of ovarian cancer | |
IL271256A (en) | Compositions and methods for treating tauopathies | |
IL314823A (en) | Anti-folr1 immunoconjugates and anti-pd-1 antibody combinatinos | |
LT3293201T (en) | Combining adenovirus and checkpoint inhibitors for treating cancer | |
IL272669A (en) | Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer | |
EP3519592A4 (en) | Materials and methods for evaluating and treating cancer |